Pieris Pharma Cmn (PIRS) 1.68 $PIRS
Pieris Pharmaceuticals to Host Second Quarter 2016 Investor Call and Corporate Update on August 11, 2016
Marketwire Canada - Mon Aug 01, 7:01AM CDT
BOSTON, MA--(Marketwired - August 01, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, will host a second quarter 2016 investor conference call on Thursday, August 11, 2016 at 10:00 am Eastern time to discuss financial results and provide a corporate update.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals Announces Closing of $16.5 Million Private Placement
Marketwired - Wed Jun 08, 10:21AM CDT
BOSTON, MA--(Marketwired - June 08, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) today announced closing of the private placement consisting of 8,188,804 units at a price of $2.015 per unit, for total gross proceeds of approximately $16.5 million, before deducting placement agent fees and offering expenses.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals Announces $16.5 Million Private Placement
Marketwire Canada - Fri Jun 03, 8:01AM CDT
BOSTON, MA--(Marketwired - June 03, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) announced today that it entered into a securities purchase agreement for a private placement with a select group of institutional investors, including lead investor BVF Partners L.P. and its affiliates as well as existing and new investors. The private placement will consist of 8,188,804 units, at a price of $2.015 per unit, for gross proceeds of approximately $16.5 million, before deducting placement agent fees and offering expenses. Each unit will consist of (i) one share of Pieris' common stock or non-voting series A convertible preferred stock convertible into one share of common stock, (ii) 0.40 warrants to purchase one share of common stock at an exercise price of $2.00 per share and (iii) 0.20 warrants to purchase one share of common stock at an exercise price of $3.00 per share. Each share of non-voting series A convertible preferred stock is priced at $2,015 per share, and is convertible into 1,000 shares of Pieris common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would own more than 9.99% of the total number of shares of Pieris common stock then outstanding. The warrants will be exercisable for a period of five years from the date of issuance. The closing of the financing is expected to take place on or about June 8, 2016, and is subject to standard closing conditions. Pieris expects to use the proceeds from the financing towards further development and pre-clinical and clinical work of the Company's proprietary Anticalin® product portfolio, including product candidates PRS-080, PRS-060 and PRS-343 programs, as well as the development of other programs and product candidates, and general corporate purposes.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals reports 1Q loss
Automated Insights - Wed May 11, 4:04PM CDT
FREISING-WEIHENSTEPHAN, Germany (AP) _ Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $4.2 million in its first quarter.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals Reports Financial Results and Corporate Update for the First Quarter Ended March 31, 2016
Marketwire Canada - Wed May 11, 4:00PM CDT
Company to Host an Investor Conference Call on Thursday, May 12, 2016 at 10:00 AM ET
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals to Host First Quarter 2016 Investor Call and Corporate Update on May 12, 2016
Marketwired - Wed Apr 27, 7:01AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, will host a first quarter 2016 investor conference call on Thursday, May 12, 2016 at 10:00 am Eastern time to discuss financial results and provide a corporate update.
PIRS: 1.68 (-0.02)
Enumeral and Pieris Pharmaceuticals Enter into License and Transfer Agreement
BusinessWire - Mon Apr 18, 5:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it has entered into a License and Transfer Agreement (the "License Agreement" with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, "Pieris".
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update
Marketwired - Tue Mar 22, 3:05PM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today 2015 corporate highlights, a clinical development overview and financial results for the fiscal year ending December 31, 2015.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data for Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR)
Marketwire Canada - Thu Mar 17, 7:00AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary AnticalinA® technology platform, announced today that in vivo proof of concept data for anti-tumor activity of PRS-343, the Company's lead bispecific immuno-oncology drug candidate, will be highlighted in a poster session at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) to be held in New Orleans, April 16-20, 2016. PRS-343 binds to CD137 (4-1BB) on T cells and HER2 on tumor cells, producing tumor-targeted immune activation.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals to Present at the 18th Annual BIO CEO and Investor Conference on February 8th at 9:30 am ET
Marketwired - Thu Jan 28, 7:31AM CST
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® bio therapeutic technologies, announced today that its President and CEO, Stephen Yoder, will present at the 18th Annual BIO CEO and Investor Conference. The conference is being held February 8 - 9, 2016, at the Waldorf Astoria Hotel in New York City.
PIRS: 1.68 (-0.02)
The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist
Marketwired - Tue Dec 22, 8:01AM CST
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.
CRMD: 1.52 (-0.02), PIRS: 1.68 (-0.02), AST: 3.00 (+0.07), PPHM: 0.38 (+0.01)
Pieris Pharmaceuticals enters into first cancer immunotherapy collaboration with Roche
M2 - Wed Dec 09, 5:23AM CST
Biotechnology company Pieris Pharmaceuticals (NasdaqCM
IRS) revealed on Tuesday the execution of a research collaboration and license agreement with Roche in cancer immunotherapy (CIT).
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals to Host Second Quarter 2016 Investor Call and Corporate Update on August 11, 2016
Marketwire Canada - Mon Aug 01, 7:01AM CDT
BOSTON, MA--(Marketwired - August 01, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, will host a second quarter 2016 investor conference call on Thursday, August 11, 2016 at 10:00 am Eastern time to discuss financial results and provide a corporate update.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals Announces Closing of $16.5 Million Private Placement
Marketwired - Wed Jun 08, 10:21AM CDT
BOSTON, MA--(Marketwired - June 08, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) today announced closing of the private placement consisting of 8,188,804 units at a price of $2.015 per unit, for total gross proceeds of approximately $16.5 million, before deducting placement agent fees and offering expenses.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals Announces $16.5 Million Private Placement
Marketwire Canada - Fri Jun 03, 8:01AM CDT
BOSTON, MA--(Marketwired - June 03, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) announced today that it entered into a securities purchase agreement for a private placement with a select group of institutional investors, including lead investor BVF Partners L.P. and its affiliates as well as existing and new investors. The private placement will consist of 8,188,804 units, at a price of $2.015 per unit, for gross proceeds of approximately $16.5 million, before deducting placement agent fees and offering expenses. Each unit will consist of (i) one share of Pieris' common stock or non-voting series A convertible preferred stock convertible into one share of common stock, (ii) 0.40 warrants to purchase one share of common stock at an exercise price of $2.00 per share and (iii) 0.20 warrants to purchase one share of common stock at an exercise price of $3.00 per share. Each share of non-voting series A convertible preferred stock is priced at $2,015 per share, and is convertible into 1,000 shares of Pieris common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would own more than 9.99% of the total number of shares of Pieris common stock then outstanding. The warrants will be exercisable for a period of five years from the date of issuance. The closing of the financing is expected to take place on or about June 8, 2016, and is subject to standard closing conditions. Pieris expects to use the proceeds from the financing towards further development and pre-clinical and clinical work of the Company's proprietary Anticalin® product portfolio, including product candidates PRS-080, PRS-060 and PRS-343 programs, as well as the development of other programs and product candidates, and general corporate purposes.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals reports 1Q loss
Automated Insights - Wed May 11, 4:04PM CDT
FREISING-WEIHENSTEPHAN, Germany (AP) _ Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $4.2 million in its first quarter.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals Reports Financial Results and Corporate Update for the First Quarter Ended March 31, 2016
Marketwire Canada - Wed May 11, 4:00PM CDT
Company to Host an Investor Conference Call on Thursday, May 12, 2016 at 10:00 AM ET
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals to Host First Quarter 2016 Investor Call and Corporate Update on May 12, 2016
Marketwired - Wed Apr 27, 7:01AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, will host a first quarter 2016 investor conference call on Thursday, May 12, 2016 at 10:00 am Eastern time to discuss financial results and provide a corporate update.
PIRS: 1.68 (-0.02)
Enumeral and Pieris Pharmaceuticals Enter into License and Transfer Agreement
BusinessWire - Mon Apr 18, 5:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it has entered into a License and Transfer Agreement (the "License Agreement" with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, "Pieris". PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update
Marketwired - Tue Mar 22, 3:05PM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today 2015 corporate highlights, a clinical development overview and financial results for the fiscal year ending December 31, 2015.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data for Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR)
Marketwire Canada - Thu Mar 17, 7:00AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary AnticalinA® technology platform, announced today that in vivo proof of concept data for anti-tumor activity of PRS-343, the Company's lead bispecific immuno-oncology drug candidate, will be highlighted in a poster session at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) to be held in New Orleans, April 16-20, 2016. PRS-343 binds to CD137 (4-1BB) on T cells and HER2 on tumor cells, producing tumor-targeted immune activation.
PIRS: 1.68 (-0.02)
Pieris Pharmaceuticals to Present at the 18th Annual BIO CEO and Investor Conference on February 8th at 9:30 am ET
Marketwired - Thu Jan 28, 7:31AM CST
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® bio therapeutic technologies, announced today that its President and CEO, Stephen Yoder, will present at the 18th Annual BIO CEO and Investor Conference. The conference is being held February 8 - 9, 2016, at the Waldorf Astoria Hotel in New York City.
PIRS: 1.68 (-0.02)
The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist
Marketwired - Tue Dec 22, 8:01AM CST
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.
CRMD: 1.52 (-0.02), PIRS: 1.68 (-0.02), AST: 3.00 (+0.07), PPHM: 0.38 (+0.01)
Pieris Pharmaceuticals enters into first cancer immunotherapy collaboration with Roche
M2 - Wed Dec 09, 5:23AM CST
Biotechnology company Pieris Pharmaceuticals (NasdaqCM
IRS) revealed on Tuesday the execution of a research collaboration and license agreement with Roche in cancer immunotherapy (CIT). PIRS: 1.68 (-0.02)
